CP-065 Switching antiretroviral therapy: reasons and associated costs in a cohort of Hiv-Infected patients: Abstract CP-065 Table 1
| Autor: | A Guelar, A Retamero, Santiago Grau, Sonia Luque, E. Salas, R Garcia, Hernando Knobel, M. Florit |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Pediatrics
medicine.medical_specialty business.industry Human immunodeficiency virus (HIV) medicine.disease_cause Spearman's rank correlation coefficient Virological failure Antiretroviral therapy Cohort Hiv patients medicine Hiv infected patients General Pharmacology Toxicology and Pharmaceutics business |
| Zdroj: | European Journal of Hospital Pharmacy. 22:A25.3-A26 |
| ISSN: | 2047-9964 2047-9956 |
| Popis: | Background Several factors, such as toxicity, virological failure or low adherence can justify the need for switching antiretroviral therapy (ART) in HIV patients. Purpose To study the reasons for switching ART in an HIV unit in a tertiary hospital. Secondary objectives were to study the number of switches over time and their estimated annual cost (EAC). Material and methods We recorded ART switches performed every 6 months from January 2012–June 2014 in our cohort of 1,550 HIV-infected patients. Date collected: previous and new ART, reason for switching and EAC (difference in the daily acquisition cost between the new and the previous ART calculated for 365 days of treatment). The Spearman test was used for bivariate correlations. Results 685 switches were performed: 117 (7.5%), 98 (6.3%), 130 (8.4%), 157 (10.1%) and 183 (11.8%) in each 6-month period. An increase in the number of changes/6 months over time was observed (Spearman rho: 0.9; p < 0.05). The total number of switches/6 months correlated only with toxicity (Spearman rho: 0.95; p < 0.05). View this table: Abstract CP-065 Table 1 Reasons for switching and EAC (euros) Conclusion References and/or Acknowledgements No conflict of interest. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|